๐ฎ๐ณ ์ธ๋ ยท "GLUE" ยท ์ด 4๊ฑด
ํํฐ ๋ณด๊ธฐํ์ฌ ์ง์
48.2
0 = ๋ถ์ ์ฐ์ธ
50 = ์ค๋ฆฝ
100 = ๊ธ์ ์ฐ์ธ
์ต๊ทผ 7์ผ ๊ธฐ์ค 5,847๊ฑด์ ๋ถ์ํ ๊ฒฐ๊ณผ, ๋ด์ค ์ฌ๋ฆฌ์ง์๋ 48.2(๊ท ํ)์ ๋๋ค. ๊ธ์ 567๊ฑด(9.7%)ยท์ค๋ฆฝ 3,954๊ฑด(67.6%)ยท๋ถ์ 1,326๊ฑด(22.7%)์ด๋ฉฐ, ์ค๋ฆฝ ๋น์ค์ด ๋๋ ทํ๊ฒ ๋์ต๋๋ค. ์ฑํฅ ์ง์๋ ์ข ํฉ 12.5(์ค๋ ๊ท ํ)์ ๋๋ค.
Kharge said the INDIA bloc decided to write to the Chief Justice of India over SIR, hold more frequent meetings and seek the education ministerโs resignation
If Congress has already chosen Vijay over Stalin in Tamil Nadu, bringing TVK into the front could prevent the alliance from losing its footprint in a politically significant state
LONGVIEW, Wash: From his living room window, Washington state Sen. Jeff Wilson can see the paper mill where a chemical tank ruptured this week in Longview, killing 11 people. He used to perform work there as the owner of an environmental cleanup company, and when he heard the sirens go past, he called his son, who works on the larger industrial site, to make sure he was safe."I personally have been inside that tank and near that tank many times," said Wilson, who has lived in Longview for 56 years. "I can assure you that we all know somebody there. ... The casualties are our friends and neighbors."The tank, which contained more than 500,000 gallons (1.9 million liters) of a mixture used to break down wood for making paper, collapsed Tuesday morning at the Nippon Dynawave Packaging Co. The rupture expelled a flood of caustic chemicals powerful enough to overturn pickup trucks and damage buildings at the site.Also Read: Six dead, several injured as part of under-construction bridge collapses in Uttar PradeshThe chemical disaster, one of the deadliest U.S. workplace accidents in recent decades, has struck at the heart of a community where generations of families have worked in local mills. Longview itself was founded by a timber baron to support the first mills established there, and over its roughly century-long history, residents' lives have become intertwined with the lumber and paper industries.Supporting victims and worrying about the futureAmid immediate concern about supporting grieving families, there is also worry about what the accident could mean for the future of the plant: It provides crucial jobs in an industry that once powered the forested region but has dwindled in recent decades.The plant's parent company, Tokyo-based Nippon Paper Group, said in a statement that it was assessing the accident's impact on its financial performance."Last night at the vigils, people who work in mills told me that they're proud of their jobs and they're proud of their work, and they don't want to lose it," U.S. Rep. Marie Gluesenkamp Perez, whose district includes Longview, told reporters Wednesday.Residents who spoke with The Associated Press similarly highlighted how important those jobs are for the city."If you're a waitress, a grocery store worker, a teacher, a paraeducator as I was for 30 years - every walk of life here knows somebody and is related to somebody from these mills," Cindy Stiebritz said in the antiques store where she volunteers.Generations in the millsStiebritz said her husband's parents met while working at the lumber company owned by the city's founder, Robert A. Long."Those mills, that is the backbone of this town," Stiebritz added. "You feel like you've lost part of your family."Longview's industrial zone lies along the Columbia River and hosts timber, paper and chemical businesses. Many residents in the city of nearly 40,000 can see the facilities or the steam from the boilers from their homes, or smell the sulfuric odor of the pulp and paper industry.The city's mill history is also imprinted on its downtown, where R. A. Long Square serves as a central landmark and gathering place, including for the vigil held after the disaster. A park around a man-made lake, another project of Long, features a burst of greenery where pedestrians enjoy its walking paths or the nearby tree-lined streets.Authorities said the cause of the tank's collapse is still under investigation. The facility, which dates to 1953 and employs about 1,000 people, makes material for tissues, printing paper, cups, plates, cartons and other goods.According to fundraisers organized for the victims' families, those who lost their lives include a grandfather who was always willing to help anyone; two brothers, one of whom was the sole provider for his partner and three children; and a husband who left behind two children and a wife with a baby on the way.Brianna Pesio, a server at the Mill City Grill downtown, said her father has worked at the plant for over 30 years. She described the fear Tuesday morning when her brother, who works at the lumber mill next door, told her he couldn't get a hold of him."I just didn't know if I lost my dad or not," said Pesio, whose husband also works in a paper mill. "I drove over to my dad's house and pounded on his door until he did wake up. He had just gotten off shift at 5 a.m."At the nearby Country Folks Deli, longtime server Gayle Leavitt said her in-laws also worked at the mill for decades, adding: "That's how this town has survived."'This is not the virtual world'Officials representing the area echoed the pride residents take in the mills and the economic importance of their good-paying jobs in a region where other areas have been hit hard by the decline of the timber industry."This is a place where real people make real things. This is not the virtual world," state Rep. Jim Walsh said at a news conference at the plant on Tuesday. "Real things and real industry always carries risks. But it's our job to make sure that risk like this is well managed and, to the extent it can be, controlled."Stiebritz, the antiques shop volunteer, said she hopes authorities find out the cause "so it never happens again.""If anything comes out of it, I hope lives can be saved," she said, tearing up as she thought of the children who have lost their parents."This town is family. It's one big family," she added. "But we'll make it though. We're strong. We've got a lot of love."
One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.Chemical biologist Gregory Verdine believed you could fight disease-causing proteins hidden inside cells by chemically gluing them to something else in the body and smothering them."Everybody told us this is crazy, that it would never work," he recalls.Revolution Medicines, which bought one of Verdine's companies in 2018, recently announced that one of its drugs doubled the typical survival time for patients with aggressive forms of the disease, from 6.7 months to 13.2 months. The full results from the company's final-stage trial are expected to be the star of the show at the annual confab of cancer doctors in Chicago this weekend.Spurred by the success of RevMed, numerous companies are now racing to develop similar drugs, dubbed "molecular glues", which can be used to treat a variety of ailments. And investors and pharmaceutical companies with deep pockets are chasing after them, creating one of the hottest corners of dealmaking in the industry.Also read | India's out-of-pocket healthcare spending drops significantly, govt data showsIt's not unusual for exciting new drugs to spark surges in stock prices and dealmaking frenzy. But molecular glue is a particularly complicated science, and the startups pursuing technologies similar to RevMed are mostly in early stages of testing. Their medicines won't be ready for years, if ever.That hasn't stopped big drugmakers such as Novartis, Roche Holding and Eli Lilly from inking research pacts with glue developers that could pay out billions of dollars in milestones.The boom has been especially lucrative for Monte Rosa Therapeutics. Over the past three years, the Boston-based biotech firm has signed three agreements that could be worth over $10 billion to develop molecular glue drugs with both Novartis and Roche.The company, which trades under the stock ticker GLUE, has seen its shares surge nearly 400% over the past year. It's preparing to start mid-stage trials for multiple drugs by the end of this year."The run-up in the share price is justified based on what we've seen so far," says Robert Driscoll, an analyst at Wedbush. Gains are "due to the success of their drugs rather than kind of exuberance around the glue technology as a whole", he says.Science of GlueMolecular glues work in a fundamentally different way from other oral medicines. Most pills - like Prozac for depression or Lipitor for cholesterol - are tiny chemicals that squeeze into a pocket inside a much larger protein to gum up its functioning. But many proteins have few obvious pockets, including key cancer-causing proteins.In fact, about 80% of all proteins in the body are what scientists refer to as "undruggable", meaning they can't be targeted with traditional drug technologies.RevMed's daraxonrasib cleverly circumvents this problem by acting as a molecular stickum. Once inside the body it binds to a healthy protein on one side and then draws in the bad protein to stick to the other side. The healthy protein helps block the bad protein and turn off its signalling.Competitors Line UpMultiple companies are chasing RevMed's lead in pancreatic cancer despite the long odds. San Diego-based Erasca is in early stages of testing a drug it says is more potent than daraxonrasib. Japanese drugmaker Astellas Pharma has begun final-stage trials of a degrader that may help a subset of pancreatic and lung cancer patients.Molecular glues are also being developed as alternatives to injectable drugs used to treat autoimmune and skin disorders. Shares of Kymera Therapeutics have soared more than 180% in the past year thanks to promising early trial results. The company is developing a once-daily pill it hopes will one day compete with Sanofi and Regeneron Pharmaceuticals' Dupixent, one of the world's bestselling drugs."The technology allows you to go after things that would have been almost impossible" to do previously with pills, says Nello Mainolfi, Kymera's founder and CEO.With few effective options for pancreatic cancer, analysts expect RevMed's daraxonrasib to become an enormous bestseller for the company.Prospects for daraxonrasib and speculation about a potential takeout deal have inflated RevMed's market cap to nearly $33 billion. That's a lofty figure for a drugmaker with no approved medicines.The company is preparing to file for US approval soon, and the FDA has promised to give the drug an ultrafast review. It's projected to reach $7 billion in sales a year by 2032, according to the average of estimates compiled by Bloomberg.